title: Can we provide reperfusion therapy to all unselected patients admitted with acute myocardial infarction?
abstract: OBJECTIVE
  This study sought to assess the maximal rate of acute Thrombolysis in Myocardial Infarction (TIMI) grade 3 patency that can be achieved in unselected patients.
  
  
  BACKGROUND
  Early and complete (TIMI grade 3 flow) reperfusion is an important therapeutic goal during acute myocardial infarction. However, thrombolysis, although widely used, is often contraindicated or ineffective. The selective use of primary and rescue percutaneous transluminal coronary angioplasty (PTCA) may increase the number of patients receiving reperfusion therapy.
  
  
  METHODS
  A cohort of 500 consecutive unselected patients with acute myocardial infarction were prospectively treated using a patency-oriented scheme: Thrombolysis-eligible patients received thrombolysis (n = 257) and underwent 90-min angiography to detect persistent occlusion for treatment with rescue PTCA. Emergency PTCA (n = 193) was attempted in patients with contraindications to thrombolysis, cardiogenic shock or uncertain diagnosis and in a subset of patients admitted under "ideal conditions." A small group of patients (n = 38) underwent acute angiography without PTCA. Conventional medical therapy was used in 12 patients with contraindications to both thrombolysis and PTCA.
  
  
  RESULTS
  Ninety-eight percent of patients received reperfusion therapy (thrombolysis, PTCA or acute angiography), and angiographically proven early TIMI grade 3 patency was achieved in 78%. Among patients with TIMI grade 3 patency, thrombolysis alone was the strategy used in 37%, emergency PTCA in 40% and rescue PTCA after failed thrombolysis in 15%; spontaneous patency occurred in 8%.
  
  
  CONCLUSIONS
  Reperfusion therapy can be provided to nearly every patient (98%) with acute myocardial infarction. Rescue and direct PTCA provided effective early reperfusion to patients in whom thrombolysis failed or was excluded.
authors.affiliation: Cardiology Department, Hôpital Bichat, Paris, France.
authors.forename: J M
authors.initials: JM
authors.lastname: Juliard
authors.forename: D
authors.initials: D
authors.lastname: Himbert
authors.forename: J L
authors.initials: JL
authors.lastname: Golmard
authors.forename: P
authors.initials: P
authors.lastname: Aubry
authors.forename: G J
authors.initials: GJ
authors.lastname: Karrillon
authors.forename: A
authors.initials: A
authors.lastname: Boccara
authors.forename: H
authors.initials: H
authors.lastname: Benamer
authors.forename: P G
authors.initials: PG
authors.lastname: Steg
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D017023:Coronary Angiography; D004630:Emergencies; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D011379:Prognosis; D011446:Prospective Studies; D012720:Severity of Illness Index; D015912:Thrombolytic Therapy / Q000009:adverse effects; D016896:Treatment Outcome; D014654:Vascular Patency